Hormonal therapy and risk of breast cancer in Mexican women

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Amadou, Amina ^a   Fabre, Alban ^b,d   Torres Mejía, Gabriela ^b   Ortega Olvera, Carolina ^b   Angeles Llerenas, Angélica ^b   McKenzie, Fiona ^a   Biessy, Carine ^a   Hainaut, Pierre ^c   Romieu, Isabelle ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST FEEDING; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HISPANIC; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MIDDLE AGED; PARITY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; QUESTIONNAIRE; RISK ASSESSMENT; SOCIAL STATUS; TREATMENT DURATION;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; RISK FACTORS;

EID: 84896724279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079695     Document Type: Article

References (42)

1. Amadou A, Hainaut P, Romieu I (2013) Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol 2013: 906495.
2. Bernstein L, Teal CR, Joslyn S, Wilson J (2003) Ethnicity-related variation in breast cancer risk factors. Cancer 97: 222-229. (Pubitemid 36033843)
3. Sexton KR, Franzini L, Day RS, Brewster A, Vernon SW,et al (2011) A review of body size and breast cancer risk in Hispanic and African American women. Cancer 117: 5271-5281.
4. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A,et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448.
5. Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH,et al (2002) Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev 11: 795-800. (Pubitemid 35014880)
6. Gilliland FD, Hunt WC, Baumgartner KB, Crumley D, Nicholson CS,et al (1998) Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Am J Epidemiol 148: 683-692. (Pubitemid 28498436)
7. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727.
8. Bjelic-Radisic V, Petru E (2010) Hormonal contraception and breast cancer risk. Wien Med Wochenschr 160: 483-486.
9. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK,et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684-1692.
10. Iatrakis G, Iavazzo C, Zervoudis S, Koumousidis A, Sofoudis C,et al (2011) The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. Clin Exp Obstet Gynecol 38: 225-227.
11. Kahlenborn C, Modugno F, Potter DM, Severs WB (2006) Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 81: 1290-1302. (Pubitemid 44484967)
12. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059.
13. Beral V, Reeves G, Banks E (2005) Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 112: 692-695. (Pubitemid 40852833)
14. Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287: 734-741. (Pubitemid 34250459)
15. Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92: 2049-2058. (Pubitemid 40897429)
16. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT,et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289: 3254-3263. (Pubitemid 37430078)
17. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7: 910-918. (Pubitemid 44615945)
18. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328-332. (Pubitemid 30117736)
19. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M,et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253. (Pubitemid 37430077)
20. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B,et al (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118: 1285-1291. (Pubitemid 43185619)
21. Saether S, Bakken K, Lund E (2012) The risk of breast cancer linked to menopausal hormone therapy. Tidsskr Nor Laegeforen 132: 1330-1334.
22. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ,et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295: 1647-1657.
23. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy (2007). IARC Monogr Eval Carcinog Risks Hum 91: 1-528.
24. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B,et al (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552-553. (Pubitemid 41051931)
25. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS,et al (2007) Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 121: 2517-2523. (Pubitemid 350022423)
26. Chavarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A,et al (2012) Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol 13: e335-e343.
27. Beasley JM, Coronado GD, Livaudais J, ngeles-Llerenas A, Ortega-Olvera C,et al (2010) Alcohol and risk of breast cancer in Mexican women. Cancer Causes Control 21: 863-870.
28. Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S,et al (2010) European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev 19: 1074-1082.
29. Bronfman M, Guiscafre H, Castro V, Castro R, Gutierrez G (1988) [Strategies for improving the therapeutic patterns used in acute diarrhea in primary medical care units. II. The measurement of inequality: a methodologic strategy, analysis of the socioeconomic features of the sample]. Arch Invest Med (Mex) 19: 351-360.
30. Hormones and breast cancer (2004). Hum Reprod Update 10: 281-293.
31. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B,et al (2010) Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46: 2275-2284.
32. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J,et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156: 635-648.
33. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448-454. (Pubitemid 40279968)
34. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K,et al (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100: 2328-2337. (Pubitemid 38657879)
35. Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112: 130-134. (Pubitemid 39249500)
36. Jernstrom H, Bendahl PO, Lidfeldt J, Nerbrand C, Agardh CD,et al (2003) A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 14: 673-680. (Pubitemid 37211124)
37. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N,et al (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109: 721-727. (Pubitemid 38405620)
38. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427.
39. Li R, Gilliland FD, Baumgartner K, Samet J (2002) Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women. Cancer 95: 960-968. (Pubitemid 34925344)
40. Purmonen S, Manninen T, Pennanen P, Ylikomi T (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep 19: 1627-1634.
41. Urban M, Banks E, Egger S, Canfell K, O'Connell D,et al (2012) Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med 9: e1001182.
42. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL,et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6: 798-808. (Pubitemid 41430721)